STOCK TITAN

Co-Diagnostics (CODX) Stock News, Jun-Aug 2026

CODX NASDAQ

Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.

Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX)/b) reported that Chief Commercialization Officer Seth Egan participated in the Salt Lake Business Journal's 2026 Medical Devices and Innovation Roundtable on August 13 in Salt Lake City, Utah. The 90-minute session, moderated by law firm Maschoff Brennen, gathered industry stakeholders to discuss innovation, AI’s impact on medical devices, data interoperability and commercialization strategies.Co-Diagnostics also highlighted its recent 510(k) premarket notification submission to the FDA for the Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro platform. The point-of-care Co-Dx PCR platform, conceived during the pandemic, remains under FDA and other regulatory review and is not yet cleared or available for sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.97%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) reported second quarter 2026 revenue of $0.17 million, slightly above $0.16 million a year earlier, with a net loss of $6.3 million, or $1.46 per share, versus a $7.7 million loss, or $7.00 per share, in 2025.

Operating expenses declined to $6.3 million from $8.2 million, improving operating loss to $6.2 million. Adjusted EBITDA loss narrowed to $5.8 million from $7.2 million. Cash and cash equivalents were $3.6 million at June 30, 2026, down from $11.9 million at year-end 2025.

According to the company, it completed clinical and analytical studies and submitted an FDA 510(k) and CLIA waiver for its Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument, advanced TB programs in India, secured Saudi manufacturing site approval, expanded a Mexico distribution agreement, and raised $3.0 million in a private placement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.04%
Tags
-
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) announced submission of a Dual FDA 510(k) premarket notification, together with a concurrent CLIA Waiver by Application, for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test to be used on the Co-Dx PCR Pro instrument in decentralized point-of-care settings.

According to Co-Diagnostics, the filing is supported by completed clinical and analytical performance studies, including a clinical trial of more than 1,400 symptomatic patients across nine U.S. sites and an analytical program of 27 studies with over 10,000 PCR test runs, including a multicenter reproducibility study. The company states that, if the CLIA waiver is granted, the test could be used in waived point-of-care environments, supporting expanded access to PCR testing. Co-Diagnostics highlights that its Co-Dx PCR platform is designed to pair lower-cost instrumentation and consumables with cloud-based data aggregation to help track localized outbreaks, but notes the platform remains under FDA and other regulatory review and is not yet available for sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.96%
Tags
none
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) announced it will release its second quarter 2026 financial results on Thursday, August 13, 2026, after market close. Management will discuss the results on a conference call and webcast the same day at 4:30 p.m. ET.

The event will feature CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Investors can access the live webcast via the Events & Webcasts page at ir.co-dx.com or join by phone using the provided toll-free and toll numbers. A replay will later be available on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
earnings date
-
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) reported two Ebola-related developments. Joint venture CoSara Diagnostics has supplied 200 SARAGENE Bundibugyo Virus Test kits to a third-party lab for analytical studies after a request from India’s Centre for Cellular and Molecular Platforms (C-CAMP), which supports India’s diagnostics preparedness.

The analytical work is expected to evaluate the assay’s limit of detection, repeatability, and reproducibility. Separately, Co-Diagnostics completed a proof-of-concept study of an extraction-free Co-Primers Ebola test on the Co-Dx PCR Pro point-of-care instrument using diluted plasma, described as the platform’s first blood-borne assay. CoSara is also developing a second-generation pan-Ebola assay for broader species detection. According to the company, the Co-Dx PCR platform and associated tests remain subject to regulatory review and are not yet available for sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.88%
Tags
partnership
-
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) announced that its Indian joint venture, CoSara Diagnostics, has initiated clinical studies in India for a tuberculosis (TB/MTB) test on the CoSara PCR Pro point-of-care instrument. According to Co-Diagnostics, PCR Pro instruments, MTB test kits and proprietary sample preparation devices have been shipped and are now deployed in select laboratories across India for TB testing evaluation.

The decentralized platform uses the company’s patented Co-Primers technology to deliver real-time PCR results in about 30 minutes via a mobile app. Co-Dx PCR platform products, including PCR test kits and a sample lysis instrument, are expected to be manufactured and distributed in India under the CoSara brand. India represents a significant share of global TB burden, making it a strategically important market for expanding access to high-quality PCR testing. The Co-Dx PCR platform, including PCR Home, PCR Pro and associated tests, remains subject to regulatory review and is not yet available for sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
partnership clinical trial
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) appointed Wes Lindsey, PhD, MBA as Chief Scientific Officer, bringing over 20 years of molecular diagnostics experience. According to Co-Diagnostics, he has led assay development teams responsible for more than a dozen FDA 510(k) submissions and CE-marked IVD assays, supporting regulatory and commercialization plans for the Co-Dx PCR platform, which remains under FDA and other regulatory review and is not yet available for sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.20%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) was invited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partner in the UNOPS Global Implementation Workshop on Near Point of Care TB Diagnostics in Bangkok, Thailand, from July 8-10, 2026.

The event gathers TB programs, labs, researchers, donors, and agencies from 21 countries to share early experience with WHO-recommended NPOC diagnostics and translate new guidelines, including tongue swabs and sputum pooling, into policy and funding plans. Co-Diagnostics will provide hands-on access to its Co-Dx PCR platform* and Co-Dx PCR MTB test, designed for decentralized TB testing, though the platform remains subject to regulatory review and is not yet available for sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) completed clinical and analytical performance studies for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. Over 1,400 patients were enrolled at 9 U.S. sites, with 27 analytical studies and more than 10,000 PCR test cup runs. Data are intended to support a Dual FDA 510(k) and CLIA Waiver by Application submission for point-of-care use, targeted for Q3 2026. The platform remains subject to regulatory review and is not yet available for sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) reported that its Vector Smart mosquito abatement district customer base now spans 21 states, with four new full laboratory installs in June 2026. The expansion aligns with a Co-Dx webinar for prospective MAD customers during National Mosquito Control Awareness Week.

Vector Smart multiplex PCR tests target West Nile, multiple encephalitis viruses, Zika, dengue and chikungunya, supporting decentralized, in-house PCR testing and faster vector-borne disease surveillance for communities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.57%
Tags
none

FAQ

What is the current stock price of Co-Diagnostics (CODX)?

Co-Diagnostics (CODX) last closed at $0.2249.

What is the market cap of Co-Diagnostics (CODX)?

The market cap of Co-Diagnostics (CODX) is approximately $2.4M.